-
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
Monday, June 9, 2025 - 10:02am | 924Read More...ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels. What Happened: Speaking on The Diary of a CEO podcast last...
-
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Tuesday, June 3, 2025 - 2:37pm | 491Read More...Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC...
-
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Monday, June 2, 2025 - 1:42pm | 471Read More...Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically...
-
What's Going On With Verastem Oncology Stock On Monday?
Monday, June 2, 2025 - 12:41pm | 577Read More...Verastem Oncology Inc (NASDAQ:VSTM) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients...
-
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Thursday, May 1, 2025 - 2:46pm | 617Read More...Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant...
-
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Monday, April 28, 2025 - 9:14am | 380Read More...Revvity Inc. (NYSE:RVTY) stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings. The Waltham, Massachusetts-based company reported first-quarter sales of $664.76 million, down from $709.07 million, beating the consensus of $661.18 million...
-
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Tuesday, April 15, 2025 - 3:15pm | 511Read More...Novavax, Inc. (NASDAQ:NVAX) on Tuesday released preliminary results from the SHIELD-Utah study investigating the effects of systemic and local reactogenicity of COVID-19 vaccine doses in Utah. SHIELD-Utah was a prospective, interventional study conducted at the University...
-
How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings
Tuesday, April 15, 2025 - 8:35am | 489Read More...Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16. Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott...
-
PMGC Stock Surges After Subsidiary Inks Deal With Yuva Biosciences To Develop AI Led Therapies
Thursday, April 10, 2025 - 10:47am | 423Read More...Shares of PMGC Holdings Inc. (NASDAQ:ELAB) were trading higher in premarket session Thursday, but dipped over 11% at last check. The company’s subsidiary, Northstrive Biosciences Inc., formed a development and license agreement with biotechnology innovator Yuva Biosciences Inc. to advance...
-
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs
Wednesday, April 9, 2025 - 1:43pm | 565Read More...Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million. The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader...
-
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Monday, January 13, 2025 - 3:06pm | 416Read More...Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:SAGE) that it does not already owned by Biogen for $7.22 per share. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the...
-
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Thursday, December 5, 2024 - 9:54am | 460Read More...Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. (NASDAQ:PACB), known as PacBio, is biotech’s new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios. ARK...
-
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Thursday, November 28, 2024 - 2:34am | 356Read More...Shares of Century Therapeutics Inc (NASDAQ:IPSC) zoomed by 20.74% to $1.63 per share on Wednesday, which is the highest price move in nearly a month since Oct. 1. The shares also rose the most in over 11 months since Dec. 6, 2023, in a single day. Also read: Trump’s Tariff Threat To Canada...
-
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial
Thursday, November 28, 2024 - 1:59am | 374Read More...Shares of Caballeta Bio Inc (NASDAQ:CABA) rose by 24.38% to $3.01 apiece on Wednesday and advanced by 4.65% to $3.15 per share in after-hours trading, following an update on their Systemic Sclerosis drug trial. Also read: Trump’s Tariff Threat To Canada May Disrupt Oil Markets, Inflate...
-
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Friday, November 8, 2024 - 4:14pm | 1672Read More...Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With...
















